Current Evidence of the Management of Undifferentiated Spondyloarthritis: A Systematic Literature Review

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 5, 2011, Pages

  De La Mata, Jose ^a   Maese, Jesús ^a   Martinez, Juan A ^a   Rosario, Piedad ^a   Loza, Estibaliz ^a  

^a UNIDAD DE INVESTIGACIÓN   (Spain)

Author keywords

Predominantly axial spondyloarthritis; Spondylarthritides; Spondylarthropathies; Spondylitis; Spondyloarthritis; Spondyloarthropathies treatment; Systematic review; Undifferentiated spondyloarthritis

Indexed keywords

ADALIMUMAB; CIPROFLOXACIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; DRUG EFFICACY; FUNCTIONAL STATUS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 79953043391     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.06.003     Document Type: Article

References (100)

1. Fan P., Yu D.T. Textbook of rheumatology 1993, Saunders, Philadelphia (PA). 4th ed.
2. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41(1):58-67.
3. Boyer G.S., Templin D.W., Cornoni-Huntley J.C., Everett D.F., Lawrence R.C., Heyse S.F., et al. Prevalence of spondyloarthropathies in Alaskan Eskimos. J Rheumatol 1994, 21(12):2292-2297.
4. Zochling J., Brandt J., Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) 2005, 44(12):1483-1491.
5. Mau W., Zeidler H., Mau R., Majewski A., Freyschmidt J., Stangel W., et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988, 15(7):1109-1114.
6. Braun J., Zochling J., Baraliakos X., Alten R., Burmester G., Grasedyck K., et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006, 65(9):1147-1153.
7. Flagg S.D., Meador R., Hsia E., Kitumnuaypong T., Schumacher H.R. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005, 53(4):613-617.
8. Rudwaleit M., van der Heijde D., Landewe R., Listing J., Akkoc N., Brandt J., et al. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. Ann Rheum Dis 2009, 68(6):777-783.
9. Sieper J., van der Heijde D., Landewe R., Brandt J., Burgos-Vagas R., Collantes-Estevez E., et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009, 68(6):784-788.
10. Rudwaleit M., van der Heijde D., Landewé R., Akkoc N., Brandt J., Braun J., et al. New ASAS classification criteria for peripheral spondyloarthritis. Ann Rheum Dis 2009, 68(Suppl 3):127.
11. Sackett D.L. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1986, 89(Suppl 2):2S-3S.
12. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34(10):1218-1227.
13. van der Heijde D., Calin A., Dougados M., Khan M.A., van der Linden S., Bellamy N. Selection of instruments in the core set for DC-ART. SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group Assessments in Ankylosing Spondylitis. J Rheumatol 1999, 26(4):951-954.
14. Phillips B., Ball C., Sackett D., Banedoch D., Straus S., Haynes B., et al. Levels of evidence. Oxford Centre for Evidence Based Medicine (2009, March). http://www.cebm.net/index.aspx?o=1025.
15. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin trials 1996, 17:1-12.
16. Carter J.D., Valeriano J., Vasey F.B. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol 2004, 31(10):1973-1980.
17. Sieper J., Fendler C., Laitko S., Sorensen H., Gripenberg-Lerche C., Hiepe F., et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum 1999, 42(7):1386-1396.
18. Kruithof E., De Rycke L., Roth J., Mielants H., Van den Bosch F., De Keyser F., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005, 52(12):3898-3909.
19. Maksymowych W.P., Lambert R., Jhangri G.S., Leclercq S., Chiu P., Wong B., et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001, 28(1):144-155.
20. Brandt J., Haibel H., Reddig J., Sieper J., Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002, 29(1):118-122.
21. Brandt J., Khariouzov A., Listing J., Haibel H., Sorensen H., Rudwaleit M., et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004, 31(3):531-538.
22. Schnarr S., Huelsemann J.L., Merkesdal S., Brandt J., Braun J., Prudlo-Winkler W., et al. Anti-tumor necrosis factor-alpha therapy with the chimeric monoclonal antibody infliximab in severe undifferentiated spondyloarthropathy. Ann Rheum Dis 2004, 63(Suppl 1):422.
23. Haibel H., Rudwaleit M., Listing J., Heldmann F., Wong R.L., Kupper H., et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58(7):1981-1991.
24. Barkham N., Keen H.I., Coates L.C., O'Connor P., Hensor E., Fraser A.D., et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60(4):946-954.
25. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38(5):618-627.
26. Clegg D.O., Reda D.J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42(11):2325-2329.
27. Carter J.D., Gerard H.C., Espinoza L.R., Ricca L.R., Valeriano J., Snelgrove J., et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009, 60(5):1311-1316.
28. Jones R.B., Van der Pol B., Martin D.H., Shepard M.K. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990, 162(6):1309-1315.
29. Freidank H.M., Losch P., Vogele H., Wiedmann-Al-Ahmad M. In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations. Antimicrob Agents Chemother 1999, 43(7):1808-1810.
30. Carter J.D., Espinoza L.R., Inman R.D., Sneed K.B., Ricca L.R., Vasey F.B., et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010, 62(5):1298-1307.
31. Wakefield D., McCluskey P., Verma M., Aziz K., Gatus B., Carr G. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 1999, 42(9):1894-1897.
32. Yli-Kerttula T., Luukkainen R., Yli-Kerttula U., Mottonen T., Hakola M., Korpela M., et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000, 59(7):565-570.
33. Braun J., Tuszewski M., Ehlers S., Haberle J., Bollow M., Eggens U., et al. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol 1997, 24(6):1101-1105.
34. Sandborn W.J., Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5(2):119-133.
35. Gorman J.D., Sack K.E., Davis J.C.J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346(18):1349-1356.
36. Woolacott N., Bravo Vergel Y., Hawkins N., Kainth A., Khadjesari Z., Misso K., et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006, 10(31):iii-iv. xiii-xvi, 1-239.
37. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356(9227):385-390.
38. Braun J., Bollow M., Eggens U., Konig H., Distler A., Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994, 37(7):1039-1045.
39. Heuft-Dorenbosch L., Landewe R., Weijers R., Wanders A., Houben H., van der Linden S., et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006, 65(6):804-808.
40. Oostveen J., Prevo R., den Boer J., van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 1999, 26(9):1953-1958.
41. Bennett A.N., McGonagle D., O'Connor P., Hensor E.M., Sivera F., Coates L.C., et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008, 58(11):3413-3418.
42. Baeten D., Kruithof E., Van den Bosch F., Demetter P., Van Damme N., Cuvelier C., et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001, 44(1):186-195.
43. Kruithof E., Baeten D., Van den Bosch F., Mielants H., Veys E.M., De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005, 64(4):529-536.
44. Agarwal V., Misra R. Approach to diagnosis and management of spondyloarthropathies. Journal International Medical Sciences Academy 2002, 15(1):20-24.
45. Akerkar S.M., Bichile L.S. Pamidronate: a promising new candidate for the management of spondyloarthropathy. Indian J Med Sci 2005, 59(4):165-170.
46. Allali F., Breban M., Porcher R., Maillefert J.F., Dougados M., Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003, 62(4):347-349.
47. Anandarajah A., Ritchlin C. Treatment update on spondyloarthropathy: From NSAIDs and DMARDs to anti-TNF-alpha agents. Postgraduate Medicine 2004, 116(5):31-40.
48. Anandarajah A. Advances in the treatment of rheumatoid arthritis and the spondyloarthropathies. Future Rheumatology 2007, 2(2):133-138.
49. Andreakos E., Taylor P.C., Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Current Opinion in Biotechnology 2002, 13(6):615-620.
50. Awada H., Abi-Karam G., Baddoura R., Okais J., Attoui S. Clinical, radiological, and laboratory findings in Lebanese spondylarthropathy patients according to HLA-B27 status. Joint Bone Spine 2000, 67(3):194-198.
51. Becker H., Gaubitz M., Domschke W., Kucharzik T. Treatment of arthralgias and spondyloarthropathy associated with inflammatory bowel disease. Future Rheumatology 2007, 2(4):423-431.
52. Busson M. A long-term study of flurbiprofen in rheumatological disorders: III. Other articular conditions. J Int Med Res 1986, 14(1):13-18.
53. Calguneri M., Cobankara V., Ozturk M.A., Ertenli I., Kiraz S., Apras S. Combination therapies in spondyloarthropathies. Kobe J Med Sci 2004, 50(1-2):31-37.
54. Calin A. Seronegative spondyloarthritides. Medical Clinics of North America 1986, 70(2):323-336.
55. Chamizo E. Actualización del tratamiento con AINE en espondiloartritis. Reumatol Clin 2007, 3(Supl 2):S46-S50.
56. Chen R., Du L.C., Lin Q.Q., Chen S.B., Lin L., Xu J.C., et al. Epidemiological study on spondyloarthropathy in 1982 workers and their relatives residing in Beijing urban district. Chinese Journal of Clinical Rehabilitation 2005, 9(39):148-149.
57. Dougados M. Medical treatment of spondyloarthropathies. Rev Esp Reumatol 1995, 22(6):241-246.
58. Dougados M., Revel M., Khan M.A. Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 1998, 12(4):717-736.
59. Dougados M. Disease controlling antirheumatic therapy in spondyloarthropathy. J Rheumatol Suppl 2001, 62:16-20.
60. Dougados M. Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 2001, 68(6):557-563.
61. Dubost J.J., Soubrier M., Sauvezie B. [Treatment of refractory spondylarthropathies]. Presse Med 1998, 27(4):175-180.
62. Efthimiou P., Markenson J.A. Role of biological agents in immune-mediated inflammatory diseases. South Med J 2005, 98(2):192-204.
63. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Emery P., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006, 65(Suppl 3):iii2-iii15.
64. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Sieper J., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007, 66(Suppl 3):iii2-iii22.
65. Generini S., Fiori G., Matucci Cerinic M. Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol 2002, 20(6 Suppl 28):S88-S94.
66. Godfrin B., Zabraniecki L., Lamboley V., Bertrand-Latour F., Sans N., Fournie B. Spondyloarthropathy with entheseal pain. A prospective study in 33 patients. Joint Bone Spine 2004, 71(6):557-562.
67. Haibel H., Braun J., Maksymowych W.P. Bisphosphonates-targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol 2002, 20(6 Suppl 28):S162-S166.
68. Heuft-Dorenbosch L., Landewe R., Weijers R., Houben H., van der Linden S., Jacobs P., et al. Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis 2007, 66(1):92-98.
69. Higashi S., Nakamura T., Tomoda K., Tsukano M., Sakaguchi M., Kuga F. A study of ten Japanese patients with seronegative spondylarthropathy: a tentative proposal. Mod Rheumatol 2005, 15(5):329-335.
70. Kataria R.K., Brent L.H. Spondyloarthropathies. Am Fam Physician 2004, 69(12):2853-2860.
71. Konttinen L., Kankaanpaa E., Luosujarvi R., Blafield H., Vuori K., Hakala M., et al. Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 2006, 25(6):882-884.
72. Kuek A., Hazleman B.L., Ostor A.J. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007, 83(978):251-260.
73. LaSalle S.P., Deodhar A.A. Appropriate management of axial spondyloarthritis. Curr Rheumatol Rep 2007, 9(5):375-382.
74. Lee R.Z., Veale D.J. Management of spondyloarthropathy: new pharmacological treatment options. Drugs 2002, 62(16):2349-2359.
75. Lee Y.H., Hwang J.Y., Lee S.W., Lee J. The clinical usefulness of multidetector computed tomography of the sacroiliac joint for evaluating spondyloarthropathies. Korean J Intern Med 2007, 22(3):171-177.
76. Liu Y., Cortinovis D., Stone M.A. Recent advances in the treatment of the spondyloarthropathies. Curr Opin Rheumatol 2004, 16(4):357-365.
77. Maksymowych W.P. Update in spondylarthropathy. Arthritis Rheum 2004, 51(1):143-146.
78. Maksymowych W.P., Gladman D., Rahman P., Boonen A., Bykerk V., Choquette D., et al. The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007, 34(11):2273-2284.
79. Mease P.J. Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment. Curr Opin Rheumatol 2003, 15(3):205-212.
80. Oelke K. American College of Rheumatology - 65th Annual Meeting: 10-15 November 2001, San Francisco, CA, USA. I Drugs 2002, 5(1):30-31.
81. Olivieri I., Cantini F., Salvarani C. Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. Curr Opin Rheumatol 1997, 9(4):284-290.
82. Ossandon A., Cassara E.A.M., Priori R., Valesini G. Thalidomide: focus on its employment in rheumatologic diseases. Clinical & Experimental Rheumatology 2002, Vol. 20(5)(pp 709-718).
83. Palazzi C., Padula A., Montaruli M., Pennese E., Olivieri I. Pharmacological management of undifferentiated spondyloarthropathies. Expert Opin Investig Drugs 2006, 15(1):39-46.
84. Pappagallo M., Breuer B., Schneider A., Sperber K. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 2003, 26(1):678-683.
85. Peretz A. [Inflammatory low back pain]. Rev Med Brux 2007, 28(4):290-293.
86. Queiro R., De Dios J.R. Successful treatment with low-dose weekly methotrexate in a case of undifferentiated spondyloarthropathy coexisting with cutaneous polyarteritis nodosa. Clin Rheumatol 2002, 21(4):304-305.
87. Rao U.R.K., Fatima F. Biological response modifiers. APLAR Journal of Rheumatology 2004, 7(2):179-183.
88. Reveille J.D., Arnett F.C. Spondyloarthritis: update on pathogenesis and management. Am J Med 2005, 118(6):592-603.
89. Richter M.B. Management of the seronegative spondyloarthropathies. Clin Rheum Dis 1985, 11(1):147-169.
90. Rosenbach M., Werth V.P. Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther 2007, 20(4):175-186.
91. Rudwaleit M., Baraliakos X., Listing J., Brandt J., Sieper J., Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005, 64(9):1305-1310.
92. Scherer H.U., Burmester G.R. [Biologicals in the treatment of rheumatic diseases]. Dtsch Med Wochenschr 2006, 131(41):2279-2285.
93. Toussirot E., Wendling D. [Use of methotrexate in spondylarthropathies. Review of the literature]. Rev Med Interne 1996, 17(4):333-339.
94. Toussirot E., Wendling D. Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. Drugs Aging 2005, 22(6):451-469.
95. Toussirot E., Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother 2005, 6(1):35-43.
96. van der Heijde D.M., van der Linden S. Measures of outcome in ankylosing spondylitis and other spondyloarthritides. Baillieres Clin Rheumatol 1998, 12(4):683-693.
97. Van Tubergen A.M., Landewe R.B.M., Van der Linden S. Spondylarthropathies: options for combination therapy. Springer Seminars in Immunopathology 2001, 23(1-2):147-163.
98. Veys E.M., Mielants H. Medico-surgical treatment of spondylarthropathies. Revue du Praticien 1989, 39(17):1484-1487.
99. Yang C., Huang F. Management of spondyloarthropathy in Asian countries. Current Rheumatology Reviews 2008, 4(2):131-134.
100. Yunus M.B. Current therapeutic practices in spondyloarthropathies. Compr Ther 1988, 14(2):54-64.